Stockscreener 앱 받기
11.18
1.24%
-0.14
시간 외 거래:
11.18
전일 마감가:
$11.32
열려 있는:
$11.18
하루 거래량:
2.56M
Relative Volume:
2.34
시가총액:
$1.09B
수익:
-
순이익/손실:
$-44.84M
주가수익비율:
-23.01
EPS:
-0.4858
순현금흐름:
$-44.23M
1주 성능:
-6.05%
1개월 성능:
-17.49%
6개월 성능:
+44.63%
1년 성능:
+121.83%
1일 변동 폭
$10.83
$11.56
1주일 범위
$10.63
$12.39
52주 변동 폭
$5.02
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
SPRY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.18 | 1.09B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 4% After Insider Selling - MarketBeat
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal - GlobeNewswire
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock - Investing.com
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock - MarketBeat
Ars Pharmaceuticals CEO sells $1.17 million in stock By Investing.com - Investing.com UK
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpStill a Buy? - MarketBeat
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ARS Pharmaceuticals to Present at J.P. Morgan's Prestigious Healthcare Conference - StockTitan
Franklin Resources Inc. Trims Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell Alert: Justin Chakma Sells 144,605 Shares of ARS Ph - GuruFocus.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey Sells 25,000 Shares - MarketBeat
Justin Chakma Sells 27,272 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.5%What's Next? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Ars Pharmaceuticals' chief business officer sells $1.77m in stock By Investing.com - Investing.com Australia
Ars Pharmaceuticals' chief business officer sells $1.77m in stock - Investing.com India
Ars Pharmaceuticals COO Brian Dorsey sells $493,858 in stock By Investing.com - Investing.com Australia
Ars Pharmaceuticals COO Brian Dorsey sells $493,858 in stock - Investing.com
ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy® - GlobeNewswire Inc.
ARS Pharmaceuticals seeks Asia Pacific neffy approvals By Investing.com - Investing.com Canada
Ars Pharmaceuticals' chief business officer sells shares worth $657,625 By Investing.com - Investing.com Nigeria
Ars Pharmaceuticals' chief business officer sells shares worth $657,625 - Investing.com India
ARS Pharmaceuticals seeks Asia Pacific neffy approvals - Investing.com India
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia - The Manila Times
ARS Pharma's Neffy Nasal Spray Seeks Approval in Asia-Pacific After Breakthrough Clinical Results - StockTitan
SPRYARS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - The Eastern Progress Online
Wexford Capital LP Makes New $3.60 Million Investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) Proactive Strategies - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Justin Chakma Sells 50,000 Shares - MarketBeat
Cantor Fitzgerald Analysts Lower Earnings Estimates for SPRY - MarketBeat
Ars Pharmaceuticals' chief business officer sells $2.04 million in stock By Investing.com - Investing.com Canada
Insider Sell: Justin Chakma Sells 90,000 Shares of ARS Pharmaceu - GuruFocus.com
Jacobs Levy Equity Management Inc. Buys 288,021 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell: Eric Karas Sells 10,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus.com
Ars Pharmaceuticals director Laura Shawver sells shares for $2.69 million By Investing.com - Investing.com Nigeria
Ars Pharmaceuticals chief commercial officer sells $140,423 in stock - Investing.com India
Ars Pharmaceuticals' chief business officer sells $1.2 million in stock By Investing.com - Investing.com Canada
Ars Pharmaceuticals director Laura Shawver sells shares for $2.69 million - Investing.com
Ars Pharmaceuticals' chief business officer sells $1.2 million in stock - Investing.com
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost - The Manila Times
ARS Pharmaceuticals Launches Free Nasal Spray Allergy Program for K-12 Schools, Tackles Critical Safety Need - StockTitan
Miura Global Management LLC Takes $3.92 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Neurelis Offs Neffy Stake for $208M - San Diego Business Journal
Trade Alert: Chief Business Officer & Secretary Of ARS Pharmaceuticals Justin Chakma Has Sold Stock - Simply Wall St
Connor Clark & Lunn Investment Management Ltd. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Consensus Target Price from Brokerages - MarketBeat
Insider Sell: Justin Chakma Sells 100,000 Shares of ARS Pharmace - GuruFocus.com
US Growth Stocks With High Insider Ownership For November 2024 - Simply Wall St
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):